Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2012

View Archived Issues

Phase II VTX-2337 trial in persistent ovarian cancer begins

Roche reviews highlights of third quarter 2012

Phase III MM-003 study meets primary endpoint

Study finds genetic variants associated with response to cocaine vaccine

Calcium-activated potassium channel expression investigated in Parkinson's disease model

Novel antibacterial thiolactomycin analogues presented

Chinese researchers disclose new agents for cancer

Bayer Schering Pharma prepares novel TTK inhibitors

New c-Cot inhibitors patented by Glenmark Pharmaceuticals

Researchers at Amgen patent novel protein kinase inhibitors

Duke University presents novel oligopeptides for inflammation and neurological conditions

Urine MIF could be a useful biomarker of interstitial cystitis

Astex Pharmaceuticals begins phase II study of its HSP 90 inhibitor

Seattle Genetics and Abbott expand antibody-drug conjugate collaboration

FDA accepts NDA filing for ponatinib

4SC Discovery receives research grant to develop personalized cancer drugs

Agenus begins phase II study of HerpV vaccine

Compound-loaded artificial bone acts on host cells to induce regeneration

Phase III trial of ALK-Abello's allergy vaccine meets primary endpoint

Investigator-sponsored trial of Cytori's cell therapy for scleroderma cleared in France

Xalkori granted conditional approval in Europe

Ataluren benefits selected patients with cystic fibrosis in phase III trial

EMA accepts for review lurasidone MAA

Phase III trial of reparixin in pancreatic islet transplantation enrolls first patient

Oryzon receives grant from Spanish government to develop LSD1 inhibitors for acute leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...